View of Empagliflozin Attenuates Cardiac Fibrosis via Suppression of TLR2/NF-κB Signaling in a Rat Model of Metabolic Syndrome

Return to Article Details Empagliflozin Attenuates Cardiac Fibrosis via Suppression of TLR2/NF-κB Signaling in a Rat Model of Metabolic Syndrome Download Download PDF